Saffron supplement improves retinal flicker sensitivity

Article

Short-term saffron supplementation has been found to improve retinal flicker sensitivity in early age-related macular degeneration (AMD).

Short-term saffron supplementation has been found to improve retinal flicker sensitivity in early age-related macular degeneration (AMD), according to a study recently published in Investigative Ophthalmology & Visual Science.

The study, led by Dr Benedetto Falsini of the Universita' Cattolica del S. Cuore, Rome, Italy, aimed to evaluate the functional effect that short-term saffron supplementation may have on early AMD.

A group of 25 patients with AMD were randomly assigned to oral saffron 20 mg/d or placebo supplementation for 3 months and then reverted to the reverse treatment for another 3 months. Focal electroretinograms (fERGs) and clinical findings were recorded at baseline and then after 3 months of treatment with saffron or placebo supplementation.

After the patients had received saffron supplementation their fERGs increased in amplitude compared with the baseline or those on the placebo treatment. Additionally, the fERG thresholds were decreased after saffron supplementation but not placebo.

These results show that the short-term use of saffron supplementation improves retinal flicker sensitivity in early AMD. However, these results need to be replicate and the clinical significance has not yet been quantified. Overall, the study has provided important clues that the nutritional carotenoids found in saffron may affect AMD in ways that may be beyond their antioxidant properties.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.